TY - JOUR
T1 - Re-stratification of patients with high-risk prostate cancer according to the NCCN guidelines among patients who underwent radical prostatectomy
T2 - An analysis based on the K-CaP registry
AU - Lee, Kwang Suk
AU - Koo, Kyo Chul
AU - Choi, In Young
AU - Lee, Ji Youl
AU - Hong, Jun Hyuk
AU - Kim, Choung Soo
AU - Lee, Hyun Moo
AU - Hong, Sung Kyu
AU - Byun, Seok Soo
AU - Rha, Koon Ho
AU - Chung, Byung Ha
N1 - Publisher Copyright:
© 2018 by the Korean Cancer Association.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Purpose The present study aimed to re-stratify patients with high-risk prostate cancer according to the National Comprehensive Cancer Network guidelines among patients who underwent radical prostatectomy (RP). Materials and Methods This study used the Korean Prostate Cancer Database registry and identified 1,060 patients with high-risk prostate cancer who underwent RP between May 2001 and April 2013. All patients were categorized into risk groups, and subgroups were identified according to the type and number of high-risk factors. Results Of the 1,060 high-risk patients, 599 (56.5%), 408 (38.5%), and 53 (5.0%) had 1, 2, and 3 risk factors, respectively. In multivariate analysis, the Gleason score, percentage of positive biopsy cores, and number of risk factors present were identified as independent predictors of biochemical recurrence. There were significant differences in the 5-year postoperative biochemical failure-free survival (BCFFS) rate among the different high-risk factor subgroups (log-rank p < 0.001). There were no significant differences in the BCFFS rate between the subgroup of high-risk patients with a prostate-specific antigen level > 20 ng/mL alone and the intermediate-risk group with all factors (log-rank p=0.919 and p=0.781, respectively). Additionally, no significant difference was noted in the BCFFS rate between high-risk patients having all factors and those in the very-high-risk group (p=0.566). Conclusion We successfully re-stratified patients with high-risk prostate cancer and identified the combinations of high-risk criteria that will help in the selection of patients for RP.
AB - Purpose The present study aimed to re-stratify patients with high-risk prostate cancer according to the National Comprehensive Cancer Network guidelines among patients who underwent radical prostatectomy (RP). Materials and Methods This study used the Korean Prostate Cancer Database registry and identified 1,060 patients with high-risk prostate cancer who underwent RP between May 2001 and April 2013. All patients were categorized into risk groups, and subgroups were identified according to the type and number of high-risk factors. Results Of the 1,060 high-risk patients, 599 (56.5%), 408 (38.5%), and 53 (5.0%) had 1, 2, and 3 risk factors, respectively. In multivariate analysis, the Gleason score, percentage of positive biopsy cores, and number of risk factors present were identified as independent predictors of biochemical recurrence. There were significant differences in the 5-year postoperative biochemical failure-free survival (BCFFS) rate among the different high-risk factor subgroups (log-rank p < 0.001). There were no significant differences in the BCFFS rate between the subgroup of high-risk patients with a prostate-specific antigen level > 20 ng/mL alone and the intermediate-risk group with all factors (log-rank p=0.919 and p=0.781, respectively). Additionally, no significant difference was noted in the BCFFS rate between high-risk patients having all factors and those in the very-high-risk group (p=0.566). Conclusion We successfully re-stratified patients with high-risk prostate cancer and identified the combinations of high-risk criteria that will help in the selection of patients for RP.
UR - http://www.scopus.com/inward/record.url?scp=85040446065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040446065&partnerID=8YFLogxK
U2 - 10.4143/crt.2016.494
DO - 10.4143/crt.2016.494
M3 - Article
C2 - 28279067
AN - SCOPUS:85040446065
SN - 1598-2998
VL - 50
SP - 88
EP - 94
JO - Cancer Research and Treatment
JF - Cancer Research and Treatment
IS - 1
ER -